Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated Aug. 1, 2021:
Effective Aug. 1, 2021:
Effective Sept. 1, 2021:
- HEMLIBRA
- Hemophilia Factor IX
- Hemophilia Factor VIII
- Human Fibrinogen Concentrate
- Selective Serotonin Inverse Agonist (SSIA)
- Topiramate ER
- Weight Loss Agents (applies to Kansas Turnpike Authority (KTA) only)
- Denosumab - Osteoporosis
- Denosumab - Oncology
- Acute Migraine Agents
- Verquvo
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.